Ryu Seung-Duk, Park Chang-Shin, Hwang Sung-Yeoun, Park Yeong-Chul, Chung Woon-Gye
Department of Pharmacology and Medicinal Toxicology Research Center, Inha University, Inchon, South Korea.
J Ethnopharmacol. 2005 Oct 3;101(1-3):197-203. doi: 10.1016/j.jep.2005.04.016.
We evaluated the pharmacological properties and spasmogenic activities of Yumijangquebotrade mark, a Korean herbal laxative formulation. Doses in the range 12-50 microg/ml induced a large spasmogenic effect in isolated guinea pig ileum, similar to that induced by acetylcholine. Pre-treating the tissue with atropine (0.2 microM) completely abolished the contractile effect of Yumijangquebo. The spasmogenic effect of Yumijangquebo and the inhibition of this effect by atropine suggest that a cholinergic mechanism is responsible for its effects. Yumijangquebo increased the gastrointestinal motility in ICR mice at doses between 10 and 37 mg/kg. Yumijangquebo exhibited higher activity than three other laxatives tested, which had activities about 85% of that of Yumijangquebo. In an acute toxicity study using Sprague-Dawley rats, the median lethal dose (LD50) of Yumijangquebo was greater than 2000 mg/kg, and we found no pathological changes in macroscopic examination by necropsy of rats treated with Yumijangquebo. We conclude that Yumijangquebo may be safely used as a herbal spasmogenic laxative agent.
我们评估了韩国草药泻药制剂Yumijangquebo的药理特性和致痉活性。12 - 50微克/毫升范围内的剂量在离体豚鼠回肠中诱导出较大的致痉效应，类似于乙酰胆碱所诱导的效应。用阿托品（0.2微摩尔）预处理组织可完全消除Yumijangquebo的收缩效应。Yumijangquebo的致痉效应以及阿托品对该效应的抑制表明，胆碱能机制是其发挥作用的原因。Yumijangquebo在10至37毫克/千克的剂量下可增加ICR小鼠的胃肠蠕动。Yumijangquebo的活性高于其他三种受试泻药，后三者的活性约为Yumijangquebo的85%。在一项使用Sprague-Dawley大鼠的急性毒性研究中，Yumijangquebo的半数致死剂量（LD50）大于2000毫克/千克，并且我们在对接受Yumijangquebo治疗的大鼠进行尸检的宏观检查中未发现病理变化。我们得出结论，Yumijangquebo可安全地用作草药致痉性泻药。
